BNP Paribas Financial Markets Cuts Position in Amedisys, Inc. (NASDAQ:AMED)

BNP Paribas Financial Markets lowered its stake in shares of Amedisys, Inc. (NASDAQ:AMEDFree Report) by 9.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,170 shares of the health services provider’s stock after selling 778 shares during the period. BNP Paribas Financial Markets’ holdings in Amedisys were worth $692,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted its stake in shares of Amedisys by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 9,145 shares of the health services provider’s stock worth $840,000 after acquiring an additional 177 shares in the last quarter. Signaturefd LLC raised its holdings in Amedisys by 20.9% during the third quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock worth $132,000 after purchasing an additional 236 shares during the last quarter. State of Alaska Department of Revenue boosted its position in Amedisys by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 3,782 shares of the health services provider’s stock worth $365,000 after purchasing an additional 255 shares in the last quarter. CWM LLC grew its holdings in Amedisys by 14.5% in the third quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock valued at $211,000 after purchasing an additional 277 shares during the last quarter. Finally, Creative Planning increased its position in shares of Amedisys by 7.4% in the second quarter. Creative Planning now owns 4,295 shares of the health services provider’s stock valued at $394,000 after buying an additional 295 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Price Performance

Amedisys stock opened at $85.60 on Friday. The firm has a market capitalization of $2.80 billion, a PE ratio of 33.97, a P/E/G ratio of 1.85 and a beta of 0.73. Amedisys, Inc. has a 52 week low of $84.06 and a 52 week high of $98.95. The firm’s 50-day simple moving average is $92.87 and its 200 day simple moving average is $95.02. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMEDGet Free Report) last released its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $587.67 million during the quarter, compared to analyst estimates of $586.75 million. During the same quarter in the prior year, the company earned $0.98 earnings per share. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. On average, equities research analysts predict that Amedisys, Inc. will post 4.45 EPS for the current fiscal year.

Amedisys Profile

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

See Also

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMEDFree Report).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.